Bayer's asundexian succeeds in Phase 3 stroke prevention trial, becoming first FXIa inhibitor to show positive results and potentially opening door for safer blood clot medications.
Johnson & Johnson acquires Halda Therapeutics for $3.05B, gaining innovative prostate cancer treatment and platform technology for multiple solid tumors.
Bristol Myers Squibb and Johnson & Johnson have stopped a major Phase 3 trial of milvexian for acute coronary syndrome after an interim review showed the drug is unlikely to meet its main goals. Other trials continue with results expected in 2026.
Novartis acquires Avidity Biosciences for $12 billion, gaining access to breakthrough RNA therapeutics for neuromuscular diseases as the Swiss drugmaker prepares for upcoming patent expirations on key drugs.
J&J is spinning off its slower-growing $9.2B DePuy Synthes joint replacement business to focus on high-profit drugs and handle US price demands.
Johnson & Johnson is reportedly discussing the purchase of Protagonist Therapeutics. This move could boost J&J's drug portfolio, especially in treatments for immune conditions and blood cancers.
